The Hepatitis B with Delta Agent Problems of Therapy
ST Tobokalova1*, KA Nogoybaeva1 and JT Aitieva2
1Kyrgyz State Medical Institute of Postgraduate Education N. S.B. Daniarov, Bishkek, Kyrgyz Republic
2Osh State university, Osh, Kyrgyz Republic
*Corresponding Author: ST Tobokalova, Kyrgyz State Medical Institute of Postgraduate Education N. S.B. Daniarov, Bishkek, Kyrgyz Republic.
Received:
May 31, 2021; Published: July 19, 2021
Abstract
Thus, to date, the only approved etiotropic drug for viral hepatitis D is - peg IFN, which is combined with nucleoside analogues in the presence of an HBV viral load. According to systematic data for example, the use of humanized mice as a laboratory model made it possible to better understand the issues of hepatitis virus replication and integration D with host cells. As a result, researchers have developed several antiviral drugs aimed at different parts of the pathogenesis of HDV infection.
Prenylation inhibitor-Lonafarnib, which blocks the exit of HDV particles from the cell; nucleic acid polymers (NAP) (REP2139Ca), an oligopeptide that mainly affects the penetration of the virus into the cell, and Myrcludex B- lipopeptide, preventing the formation of HDV RNA in initialized hepatocytes, undergoing various phases of testing in different countries.
Keywords: Hepatitis D Infection; Antiviral Therapy; Lonafarnib; Myrcludex B
References
- Patel EU., et al. “Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011‐2016”. Clinical Infectious Diseases 69 (2019): 709‐712.
- Romeo R., et al. “A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma”. Gastroenterology 136 (2009): 1629-1638.
- Vincent TL., et al. “Targeting the Host for New Therapeutic Perspectives in Hepatitis D”. Clinical Medicine 9 (2020): 1.
- Rizzetto M., et al. “Treatment of chronic delta hepatitis with α-2 recombinant interferon”. Journal of Hepatology 3 (1986): S229-S233.
- Wedemeyer H., et al. “Peginterferon plus adefovir versus either drug alone for hepatitis delta”. The New England Journal of Medicine 364 (2011): 322-331.
- Wranke A., et al. “Current management of HBV/HDV coinfection and future perspectives”. Current Hepatology Reports 14 (2015): 284-292.
- Zoulim F., et al. “Quantification of HbsAg in nucleos (t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the be-low study”. Journal of Hepatology 62 (2015): 56-63.
- Lampertico P., et al. “EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection”. Journal of Hepatology (2017).
- Soriano V., et al. “Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients”. AIDS 28 (2014): 2389-2394.
- Wedemeyer H., et al. “Peginterferon plus adefovir versus either drug alone for hepatitis delta”. The New England Journal of Medicine 364 (2011): 322-331.
- Wedemeyer H., et al. “O4 prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2A plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: The HIDIT-2 study”. Journal of Hepatology 60 (2014): S2-S3.
- Florian A., et al. “Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen”. Viruses 7 (2017): 172.
- Koh C., et al. “Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2a trial”. Lancet Infectious Disease 15 (2015): 1167-1174.
- Rizzetto M and A Ciancio. “The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta”. Lancet Infectious Disease 15 (2015): 1119-1120.
- Bordier BB., et al. “In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus”. Journal of Clinical Investigation 112 (2003): 407-414.
- Mijimolle N., et al. “Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development”. Cancer Cell 7 (2005): 313-324.
- Palsuledesai CC., et al. “Protein prenylation: Enzymes, therapeutics, and biotechnology applications”. ACS Chemical Biology 10 (2015): 51-62.
- Yurdaydin C. “Recent advances in managing hepatitis D. Version 1”. F1000 Research 6 (2017): 1596.
- Bazinet M., et al. “Hdv2 o-09: Rep 2139 monotherapy and combination therapy with pegylated interferon: Safety and potent reduction of HbsAg and HDV RNA in patients with chronic HBV/HDV co-infection”. Journal of Viral Hepatitis 22 (2015): 5-6.
- Noordeen F., et al. “Therapeutic antiviral effect of the nucleic acid polymer rep 2055 against persistent duck hepatitis B virus infection”. PloS ONE 10 (2015): e0140909.
- “Replicor” (2017).
- Schulze A., et al. “Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction”. Journal of Virology 84 (2010): 1989-2000.
- Meier A., et al. “Myristoylated PRES1-domain of the hepatitis B virus l-protein mediates specific binding to differentiated hepatocytes”. Hepatology 58 (2013): 31-42.
- Lempp FA., et al. “Hepatitis delta virus: Insights into a peculiar pathogen and novel treatment options”. Nature Reviews Gastroenterology and Hepatology 13 (2016): 580-589.
- Nkongolo S., et al. “Cyclosporin a inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor”. Journal of Hepatology 60 (2014): 723-731.
- Haag M. “Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: Monitoring hepatitis B therapy by a novel Na (+)-taurocholate cotransporting polypeptide inhibitor”. Analytical and Bioanalytical Chemistry 407 (2015): 6815-6825.
- Slijepcevic D., et al. “Impaired uptake of conjugated bile acids and hepatitis B virus PRES1-binding in Na (+) -taurocholate cotransporting polypeptide knockout mice”. Hepatology 62 (2015): 207-219.
- Lin H., et al. “Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype”. Hepatology 61 (2015): 260-267.
- Deng M. “Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency”. Experimental and Therapeutic Medicine 12 (2016): 3294-3300.
- Blank A., et al. “First-in-human application of the first-in-class hepatitis B and hepatitis D virus entry inhibitor myrcludex B”. Journal of Hepatology 65 (2016): 483-489.
- Bogomolov P., et al. “A proof-of-concept phase 2a clinical trial with HBV/HDV entry inhibitor myrcludex b”. Hepatology 60 (2014): 1279A-1280A.
- Bogomolov P., et al. “Treatment of chronic hepatitis D with the entry inhibitor myrcludex b—First results of a phase Ib/Iia study”. Journal of Hepatology 65 (2016): 490-498.
- Elazar M and JS Glenn. “Emerging concepts for the treatment of hepatitis delta”. Current Opinion on Virology 24 (2017): 55-59.
Citation
Copyright